-
Innovation Ranking
NewInnovation Ranking – Molson Coors Brewing Co
Molson Coors Beverage Co (MCBC) produces, develops, and distributes beer and other beverage products. The company markets products under Blue Moon, Hop Valley, Molson Canadian, Cobra, Coors Light, Miller High Life, Steel Reserve, Coors, Lowenbrau, Kamenitza, Molson Ultra, Sharp's, Molson Canadian, Niksicko, Ozujsko, and Belgian White, among others. The company has manufacturing facilities in Canada, the US, Europe, Middle East, and Asia-Pacific. It distributes products through on-premise and off-premise channels that include bars, restaurants, convenience stores, grocery stores, liquor stores,...
-
Company Insights
Innovation and Patenting activity of Budweiser Brewing Company APAC Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Budweiser Brewing Company APAC Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Diffuse Large B-Cell Lymphoma Drug Details: CG-806 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Mantle Cell Lymphoma Drug Details: CG-806 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Follicular Lymphoma Drug Details: CG-806 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Luxeptinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luxeptinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luxeptinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: CG-806 is...
-
Thematic Analysis
NewWeb3 – Thematic Intelligence
Web3 Thematic Report Overview Web3 is an ideology that refers to the next model of the internet built on blockchain. It promises a mix of peer-to-peer (P2P) communication channels and decentralized governance. This will lead the internet’s transition from an information-centric model to a user-centric model. Furthermore, Web3 aims to give users the ability to create, own, and monetize their content and manage the use of their data. However, it is still an emerging model and has a long way...
-
Sector Analysis
Business of the National Football League (NFL) 2023-24 – Property Profile, Sponsorship and Media Landscape
Explore trends and actionable insights from the following data in our ‘Business of National Football League (NFL) 2023-2024’ report: Details of the financial revenue generators across the professional American football league. Ranking of competing teams based on commercial revenue and insights with a particular focus on the sponsorship and media revenue generated for the 2023-2024 season. Analysis of main commercial deals with major sponsors such as Anheuser-Busch, PepsiCo, Verizon, Ticketmaster, Miller Brewing, Coca-Cola, Toyota, BetMGM, Bose, Proctor & Gamble, Geico, Ford, FedEx,...